Skip to main content
SpringerLink
Log in

Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms

  • Published:
Journal of Thrombosis and Thrombolysis Aims and scope Submit manuscript

Abstract

Few data are available regarding epidemiology and outcomes of Philadelphia-negative chronic myeloproliferative neoplasms (MPN) in Latin America. Therefore, current models for MPN treatment are based in large cohorts of patients from Europe and North America. In this paper, we conducted a retrospective study to evaluate thrombotic and bleeding events in a cohort of patients with MPN from a reference center in Brazil. A total of 334 patients were included, being essential thrombocythemia the most common diagnosis. Here, we found that 41% of the MPN patients had a thrombotic event prior to the diagnosis. Thrombosis was more frequent in patients under 60 years-old. In a multivariable model, only JAK2 V617F mutation (OR 2.57 95% CI 1.58–4.18, p < 0.001) and presence of two cardiovascular risk factors (OR 1.90 95% CI 1.21–2.98, p < 0.005) were significant for thrombosis. The risk of thrombosis was similar among all subtypes of MPN. Cumulative incidence of thromboembolic event at 5 years from diagnosis was 5.8% (95% CI 3.5–8.9), which is similar to previous studies. The high incidence of thromboembolic events in younger patients suggests that socioeconomic disparities might have a role in the outcomes of MPN

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Gilbert HS, Dameshek W (1970) The myeloproliferative disorders. Dis Month 16:1–52

    Article  Google Scholar 

  2. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M et al (2006) MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med 3(7):e270. https://doi.org/10.1371/journal.pmed.0030270

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  3. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al (2014) Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 123(10):1552–1555

    Article  CAS  PubMed  Google Scholar 

  4. James C, Ugo V, Le Couédic J-P, Staerk J, Delhommeau F, Lacout C et al (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148

    Article  CAS  PubMed  Google Scholar 

  5. Tefferi A (2007) JAK2 mutations and clinical practice in myeloproliferative neoplasms. Cancer J 13(6):366–371

    Article  CAS  PubMed  Google Scholar 

  6. Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al (2014) JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 123(10):1544–1551

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7):1299–1307

    Article  PubMed  Google Scholar 

  8. Hultcrantz M, Kristinsson SY, Andersson TML, Landgren O, Eloranta S, Derolf ÅR et al (2012) Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 20(24):2995–3001

    Article  Google Scholar 

  9. Szuber N, Mudireddy M, Nicolosi M, Penna D, Vallapureddy RR, Lasho TL et al (2019) 3023 mayo clinic patients with myeloproliferative neoplasms: risk-stratified comparison of survival and outcomes data among disease subgroups. Mayo Clin Proc 94(4):599–610

    Article  PubMed  Google Scholar 

  10. Van Genderen PJJ, Mulder PGH, Waleboer M, Van De Moesdijk D, Michiels JJ (1997) Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol 97(1):179–84

    Article  PubMed  Google Scholar 

  11. Abdulkarim K, Samuelsson J, Johansson P, Andréasson B (2017) Risk factors for vascular complications and treatment patterns at diagnosis of 2389 PV and ET patients: real-world data from the Swedish MPN registry. Eur J Haematol 98(6):577–583. https://doi.org/10.1111/ejh.12873

    Article  PubMed  CAS  Google Scholar 

  12. De Stefano V, Za T, Rossi E, Vannucchi AM, Ruggeri M, Elli E et al (2008) Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica 93(3):372–380

    Article  CAS  PubMed  Google Scholar 

  13. Tefferi A, Vannucchi AM, Barbui T (2018) Polycythemia vera treatment algorithm. Blood Cancer J 8(1):3

    Article  PubMed  PubMed Central  Google Scholar 

  14. Barbui T, Vannucchi AM, Buxhofer-Ausch V, De Stefano V, Betti S, Rambaldi A et al (2015) Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J 5(11):e369

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Passamonti F, Thiele J, Girodon F, Rumi E, Carobbio A, Gisslinger H et al (2012) A prognostic model to predict survival in 867 World Health Organization - Defined essential thrombocythemia at diagnosis: A study by the International Working Group on Myelofibrosis Research and Treatment. Blood 9(6):1197–1201

    Article  CAS  Google Scholar 

  16. Barbui T, Finazzi G, Carobbio A, Thiele J, Passamonti F, Rumi E et al (2012) Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis). Blood 120(26):5128–5133

    Article  CAS  PubMed  Google Scholar 

  17. Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R et al (2007) Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood. 109(6):2446–52

    Article  CAS  PubMed  Google Scholar 

  18. Alvarez-Larrán A, Pereira A, Guglielmelli P, Hernández-Boluda JC, Arellano-Rodrigo E, Ferrer-Marín F et al (2016) Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. Haematologica 101(8):926–931

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. De Stefano V, Rossi E, Carobbio A, Ghirardi A, Betti S, Finazzi G et al (2018) Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases. Blood Cancer J 8(11):112

    Article  PubMed  PubMed Central  Google Scholar 

  20. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C et al (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350(2):114–124

    Article  CAS  PubMed  Google Scholar 

  21. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405

    Article  CAS  PubMed  Google Scholar 

  22. Didone A, Nardinelli L, Marchiani M, Ruiz ARL, de Lima Costa AL, Lima IS et al (2016) Comparative study of different methodologies to detect the JAK2 V617F mutation in chronic BCR-ABL1 negative myeloproliferative neoplasms. Pract Lab Med 4:30–37

    Article  PubMed  Google Scholar 

  23. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG (2009) Research electronic data capture (REDCap): a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 42(2):377–381

    Article  PubMed  Google Scholar 

  24. Kaifie A, Kirschner M, Wolf D, Maintz C, Hänel M, Gattermann N et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9(1):18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Soyer N, Haznedaroğlu İC, Cömert M, Çekdemir D, Yılmaz M, Ünal A et al (2017) Multicenter retrospective analysis of Turkish patients with chronic myeloproliferative neoplasms. Turk J Haematol 34(1):27–33

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Enblom A, Lindskog E, Hasselbalch H, Hersby D, Bak M, Tetu J et al (2015) High rate of abnormal blood values and vascular complications before diagnosis of myeloproliferative neoplasms. Eur J Intern Med. https://doi.org/10.1016/j.ejim.2015.03.009

    Article  PubMed  Google Scholar 

  27. De Stefano V, Qi X, Betti S, Rossi E (2016) Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost 115(2):240–249

    Article  PubMed  Google Scholar 

  28. Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R et al (2018) Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia 32:1057–1069

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

    Fernanda Salles Seguro, Larissa Lane Cardoso Teixeira, Luciana Nardinelli, Israel Bendit & Vanderson Rocha

  2. Instituto do Câncer do Estado de São Paulo da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil

    Fernanda Salles Seguro, Lidiane Inês da Rosa & Wellington Fernandes da Silva

Authors
  1. Fernanda Salles Seguro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Larissa Lane Cardoso Teixeira
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lidiane Inês da Rosa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wellington Fernandes da Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Luciana Nardinelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Israel Bendit
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vanderson Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fernanda Salles Seguro.

Ethics declarations

Conflicts of interest

The authors declare no conflicts of interest in preparing this article.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Seguro, F.S., Teixeira, L.L.C., da Rosa, L.I. et al. Risk factors and incidence of thrombosis in a Brazilian cohort of patients with Philadelphia-negative myeloproliferative neoplasms. J Thromb Thrombolysis 49, 667–672 (2020). https://doi.org/10.1007/s11239-019-02029-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11239-019-02029-y

Keywords

Search

Navigation